



Drugs Misuse Act 1986

Drugs Misuse Regulation 1987

Current as at 1 July 2013

Information about this reprint

This reprint shows the legislation current as at the date on the cover and is authorised by the Parliamentary Counsel.

A new reprint of the legislation will be prepared by the Office of the Queensland Parliamentary Counsel when any change to the legislation takes effect. This change may be because a provision of the original legislation, or an amendment to it, commences or because a particular provision of the legislation expires or is repealed.

When a new reprint is prepared, this reprint will become a historical reprint. Also, if it is necessary to replace this reprint before a new reprint is prepared, for example, to include amendments with a retrospective commencement, an appropriate note would be included on the cover of the replacement reprint and on the copy of this reprint at www.legislation.qld.gov.au.

The endnotes to this reprint contain detailed information about the legislation and reprint. For example—

- The table of reprints endnote lists any previous reprints and, for this reprint, gives details of any discretionary editorial powers under the *Reprints Act 1992* used by the Office of the Queensland Parliamentary Counsel in preparing it.
- The list of legislation endnote gives historical information about the original legislation and the legislation which amended it. It also gives details of uncommenced amendments to this legislation. For information about possible amendments to the legislation by Bills introduced in Parliament, see the Queensland Legislation Current Annotations at www.legislation.qld.gov.au/information.
- The list of annotations endnote gives historical information at section level.

All Queensland reprints are dated and authorised by the Parliamentary Counsel. The previous numbering system and distinctions between printed and electronic reprints are not continued.



Queensland

Drugs Misuse Regulation 1987

Contents

		Page
Part 1	Preliminary	
1	Short title	5
2	Dictionary	5
Part 2	Syringes and dangerous drugs disposal procedures	
3	Prescribed procedures for the disposal of hypodermic syringes and needles	5
4	Prescribed procedure for disposal of dangerous drugs	6
Part 3	Controlled substances	
5	Other act that is a relevant transaction—Act, s 43C(b)	6
6	Documents and proof of identity required for supply of a controlled substance or controlled thing—Act, s 43D(1)(a)	7
6A	End user declaration to be given to commissioner of police service—Act, s 43D(1)(d)	8
7	Details about supply of controlled substance or controlled thing to be recorded in register	8
8	Details about loss or theft of controlled substance or controlled thing to be recorded in register	10
9	Keeping of register, invoice and other documents	10
Part 4	Commercial production of industrial cannabis	
Division 1	Preliminary	
10	Operation of pt 4 and schs 7 and 8	11
Division 2	Certified cannabis seed	
11	Certifying cannabis seed	11
Division 3	Carriers	
12	Application of div 3	12
13	Supply	12
14	Possession	13
Division 4	DPI researchers	
15	Supply	13

Contents

16	Production	14
17	Possession	14
Division 5	Inspectors	
18	Supply	15
19	Possession	15
Division 6	Seed suppliers	
20	Supply	16
21	Possession	16
Division 7	Other persons	
22	Denaturer	16
23	Manufacturer	17
24	Analyst	17
25	Family members	18
26	Employees of authorised persons	18
Division 8	Other provisions	
27	Recognition as seed supplier	19
28	Licence fees	20
29	Licence conditions—Act, s 64	20
Part 5	Transitional provisions	
30	Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2001	20
31	Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2002	21
Schedule 1	Dangerous drugs	22
Schedule 2	Dangerous drugs	23
Schedule 3	Specified quantities for particular dangerous drugs	42
Schedule 4	Specified quantities for particular dangerous drugs	44
Schedule 5	Dangerous drugs	45
Schedule 6	Controlled substances	48
Schedule 7	Conditions for particular persons authorised under part 4 .	51
1	Denaturer	51
2	DPI researcher	51
3	Inspector	52
4	Seed supplier	53
5	Analyst	54
Schedule 8	Licence conditions	55

Schedule 8A	Gross weight of relevant substances for ss 9A, 9B, 9C and 9D of Act	58
Schedule 8B	Things specified for ss 9A, 9B, 9C and 9D, and prescribed for s 134, of Act	64
Schedule 8C	Prohibited combinations of items	65
Schedule 8D	Relevant dangerous drugs	66
Schedule 9	Dictionary	67
 Endnotes		
1	Index to endnotes	69
2	Date to which amendments incorporated	69
3	Key	69
4	Table of reprints	70
5	List of legislation	71
6	List of annotations	75

Drugs Misuse Regulation 1987

[as amended by all amendments that commenced on or before 1 July 2013]

Part 1 Preliminary

1 Short title

This regulation may be cited as the *Drugs Misuse Regulation 1987*.

2 Dictionary

The dictionary in schedule 9 defines particular words used in this regulation.

Part 2 Syringes and dangerous drugs disposal procedures

3 Prescribed procedures for the disposal of hypodermic syringes and needles

For the purposes of section 10(4A) of the Act, the prescribed procedures for the disposal of a hypodermic syringe or needle are—

- (a) by placing the hypodermic syringe or needle in a rigid wall, puncture resistant container and that container is sealed or securely closed in such a manner that its contents are incapable of causing injury to any person;
- or

[s 4]

- (b) by giving the hypodermic syringe or needle to a person who is a medical practitioner, pharmacist or person or a member of a class of persons referred to as authorised in section 10(3) of the Act.

4 Prescribed procedure for disposal of dangerous drugs

For the purposes of section 125 of the Act, the prescribed procedure for the disposal of a thing is—

- (a) in the case where the thing is a trace amount of a dangerous drug contained in a hypodermic syringe or needle, by disposing of the hypodermic syringe or needle in accordance with the procedures prescribed in section 3; or
- (b) in any other case, at the first reasonable opportunity, by giving—
 - (i) such thing; and
 - (ii) where such thing is contained in a hypodermic syringe or needle, such syringe or needle;

to an inspector appointed under the *Health Act 1937*, section 137.

Part 3 Controlled substances

5 Other act that is a relevant transaction—Act, s 43C(b)

Any act by which a controlled substance is supplied by a person, in or in connection with the person's business, to anyone else is a relevant transaction for the supply of a controlled substance.

Example—

A and B are partners in a chain of pharmacies. They make cold tablets to sell in the pharmacies by compounding ephedrine (a controlled substance) with other substances.

The partners sell some of the left over ephedrine to a pharmaceutical research company and give the rest away.

Both the sale and gift of ephedrine are relevant transactions.

Editor's note—

Under section 43A of the Act—

supply means give, distribute, sell or supply.

6 Documents and proof of identity required for supply of a controlled substance or controlled thing—Act, s 43D(1)(a)

- (1) This section applies to a person who supplies a controlled substance or controlled thing under a relevant transaction to anyone else (a *recipient*).
- (2) The person must, before supplying the substance or thing, obtain from the recipient a document (an *end user declaration*) showing the following information—
 - (a) the recipient's name and address, and if the recipient purports to obtain the substance or thing for another person, the other person's name and address;
 - (b) details of the official document produced by the recipient under subsection (3) as evidence of the recipient's identity;
 - (c) the date and number of the written order for the supply of the substance or thing;
 - (d) the name and quantity of the substance or thing to be supplied;
 - (e) if a thing is supplied—the serial number or unique identifier of the thing;
 - (f) the date on which the substance or thing is to be supplied;
 - (g) the purpose for which the substance or thing is to be supplied.
- (3) If the recipient is an individual, the person must, before supplying the substance or thing, require the recipient to

[s 6A]

produce an official document containing the recipient's photograph (for example, a passport or driver licence) as evidence of the recipient's identity.

- (4) The person must, immediately the person supplies the substance or thing under the transaction, make an invoice for the supply of the substance or thing showing the following details—
 - (a) the recipient's name and address;
 - (b) the recipient's order number for the supply of the substance or thing;
 - (c) the date the substance or thing was supplied;
 - (d) the name and quantity of the substance or thing supplied.

Maximum penalty for subsection (4)—20 penalty units.

6A End user declaration to be given to commissioner of police service—Act, s 43D(1)(d)

- (1) This section applies to a person who supplies a controlled substance or controlled thing under a relevant transaction to anyone else (the *recipient*).
- (2) The person must, as soon as practicable after obtaining from the recipient the end user declaration mentioned in section 6(2), give a copy of the end user declaration to the commissioner of the police service.

7 Details about supply of controlled substance or controlled thing to be recorded in register

- (1) The following details about a relevant transaction for the supply of a controlled substance or controlled thing must be recorded in the register—
 - (a) the name and address of the recipient and, if the recipient purports to obtain the substance or thing for another person, the other person's name and address;

- (b) the recipient's order number for the supply of the substance or thing;
 - (c) the invoice number for the supply of the substance or thing;
 - (d) if the recipient is—
 - (i) a company—its Australian Company Number; or
 - (ii) an individual—the type of official document produced under section 6(3) and the following details about the document—
 - (A) who issued it;
 - (B) its serial number or other identifying number or mark;
 - (e) the name and quantity of the substance or thing supplied;
 - (f) the date the substance or thing was supplied;
 - (g) the purpose for which the substance or thing was supplied.
- (2) The details must be recorded in the register as soon as practicable, but in no case later than 7 days, after the day the person supplied the substance or thing under the transaction.
- (3) Nothing in this section prevents the keeping of a single register for the Act and another Act if—
- (a) the keeping of the single register is not contrary to the other Act; and
 - (b) the details recorded under subsection (1) are easily identifiable in the single register.

Note—

See section 43D(1)(c) of the Act for the requirement to keep the register.

[s 8]

8 Details about loss or theft of controlled substance or controlled thing to be recorded in register

The following details of the reporting to a police officer of the loss or theft of a controlled substance or controlled thing must be recorded in the register—

- (a) the day and place the report was made;
- (b) the name and registered number of the officer to whom the report was made;
- (c) the name and quantity of the substance or thing lost or stolen.

9 Keeping of register, invoice and other documents

- (1) This section applies to the register and other documents mentioned in the Act, section 43D(1) and the invoice required under section 6(4).
- (2) A person who supplies a controlled substance or controlled thing under a relevant transaction must keep the register, documents or invoice—
 - (a) at the principal or only place in Queensland where the person engages in relevant transactions; and
 - (b) for 2 years from the day the person supplied the substance or thing under the transaction.

Part 4 Commercial production of industrial cannabis

Division 1 Preliminary

10 Operation of pt 4 and schs 7 and 8

- (1) Divisions 3 to 7 state activities stated persons are authorised to perform for the purposes of part 5B of the Act.
- (2) Schedule 7 states conditions applying to particular persons who perform activities stated in divisions 4, 5, 6 and 7.
- (3) If a word used in this part, schedule 7 or schedule 8 is not defined in the dictionary but is defined for part 5B of the Act, the word has the same meaning as in that part, unless a contrary intention appears.

Note—

See section 46 of the Act for definitions for pt 5B of the Act.

Division 2 Certified cannabis seed

11 Certifying cannabis seed

- (1) The way seed originating in Queensland is to be certified for the definition *certified cannabis seed* in section 46 of the Act is stated in the Industrial Cannabis THC Seed Certification Code of Practice approved by the chief executive by gazette notice.

Editor's note—

The code is a departmental document and is published by the department. A copy of the code may be obtained or inspected without charge from the department's head office at 80 Ann Street, Brisbane during normal business hours. The department's internet site is at <www.daff.qld.gov.au> and the code is also available there.

- (2) The way cannabis seed originating in another State or a foreign country (*imported seed*) is certified for the definition

[s 12]

certified cannabis seed in section 46 of the Act is stated in subsection (3).

- (3) The seed must be in a package that—
 - (a) has a document attached to it certifying that the seed—
 - (i) has been certified in accordance with a recognised quality assurance program; and
 - (ii) if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads of not more than 0.5%; and
 - (b) describes the contents of the package as seed that, if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads of not more than 0.5%.

Division 3 Carriers

12 Application of div 3

This division applies to a carrier only if the carrier is engaged or employed by any of the following to transport consigned cannabis—

- (a) a category 1 or category 2 researcher;
- (b) a grower;
- (c) a DPI researcher;
- (d) an inspector;
- (e) a seed supplier.

13 Supply

- (1) The carrier is authorised to transport consigned cannabis and give it to the person to whom it is consigned.
- (2) The authorisation—

- (a) is for the time necessary for the carrier to transport the consigned cannabis and give it to the person to whom it is consigned; and
- (b) has effect only while the carrier is acting in accordance with the terms of the carrier's engagement or employment.

14 Possession

- (1) The carrier is authorised to possess consigned cannabis for the time necessary for the carrier to transport it to the person to whom it is consigned and give it to the person.
- (2) The authorisation has effect only while the carrier is acting in accordance with the terms of the carrier's engagement or employment.

Division 4 DPI researchers

15 Supply

A DPI researcher is authorised—

- (a) to supply class A research cannabis plants and seed to another DPI researcher or a category 1 researcher; and
- (b) to supply class B research cannabis plants and seed to another DPI researcher or a category 1 or category 2 researcher; and
- (c) to supply class A and class B research cannabis seed to a grower for use, under the DPI researcher's supervision, as part of a field trial the DPI researcher is conducting on land owned or leased by the grower; and
- (d) to supply industrial cannabis seed to any of the following—
 - (i) a grower;
 - (ii) a category 1 or category 2 researcher;

[s 16]

- (iii) another DPI researcher;
 - (iv) the owner or operator of a facility at which industrial cannabis seed may be denatured;
 - (v) the owner or operator of a facility where processed cannabis is, or is to be, used for manufacturing a manufactured product for sale by wholesale or retail; and
- (e) to supply class A or class B research cannabis seed or industrial cannabis seed to a person in another State who is authorised under the law of that State to possess cannabis seed that, if grown, will produce plants with a THC concentration in their leaves and flowering heads that the person in the other State may possess; and
 - (f) to supply class A or class B research cannabis plants, industrial cannabis plants or processed cannabis to an analyst; and
 - (g) to supply processed cannabis to the owner or operator of a facility where processed cannabis is used for manufacturing a manufactured product for sale by wholesale or retail.

16 Production

A DPI researcher is authorised to produce, for use in plant breeding programs for developing new commercial strains of industrial cannabis—

- (a) industrial cannabis plants and seed; and
- (b) class A and class B research cannabis plants and seed.

17 Possession

A DPI researcher is authorised to possess any of the following for a purpose mentioned in section 15 or 16—

- (a) industrial cannabis plants and seed;

- (b) class A and class B research cannabis plants and seed;
- (c) processed cannabis.

Division 5 Inspectors

18 Supply

An inspector is authorised—

- (a) to supply industrial cannabis plants, class A or class B research cannabis plants or processed cannabis to an analyst to analyse the THC concentration in any of them; and
- (b) if the inspector is given industrial cannabis plants or seed or class A or class B research cannabis plants or seed for delivery to a particular person who is lawfully entitled to possess the plants or seed—to supply the plants or seed to the person.

19 Possession

An inspector is authorised—

- (a) to possess industrial cannabis plants, class A or class B research cannabis plants or processed cannabis given to the inspector for delivery to an analyst to analyse the THC concentration in the plants or processed cannabis; and
- (b) to possess industrial cannabis plants or seed or class A or class B research cannabis plants or seed given to the inspector for delivery to a person lawfully entitled to possess the plants or seed.

[s 20]

Division 6 Seed suppliers

20 Supply

A seed supplier is authorised to supply industrial cannabis seed to any of the following—

- (a) a category 1 or category 2 researcher;
- (b) a grower;
- (c) a DPI researcher;
- (d) a person in another State who is authorised under the law of that State to possess cannabis seed that, if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads the person in the other State may possess;
- (e) if the seed supplier holds a licence under the *Customs Act 1901* (Cwlth) authorising the seed supplier to export cannabis—a person in a foreign country who is authorised under the law of the country to possess the seed.

21 Possession

A seed supplier is authorised to possess industrial cannabis seed for the purpose of supplying it to a person mentioned in section 20.

Division 7 Other persons

22 Denaturer

- (1) The owner or operator of a facility where industrial cannabis seed may be denatured under an agreement or arrangement with a licensee or another person authorised under this part to produce industrial cannabis seed (*denaturer*), is authorised to possess industrial cannabis seed supplied to the owner or operator, but only for the purpose of denaturing the seed.

- (2) A denaturer is authorised to supply denatured seed to a person who is authorised to possess processed cannabis.

23 **Manufacturer**

The owner or operator of a facility where processed cannabis is used for manufacturing a manufactured product for sale by wholesale or retail is authorised to possess processed cannabis for using it for manufacturing a manufactured product.

24 **Analyst**

- (1) An analyst is authorised to possess—
- (a) standard THC material to calibrate an analytical instrument used for analysing a substance to determine its THC concentration; and
 - (b) if an authorised person engages or employs the analyst to analyse a substance to determine its THC concentration—the substance for the purpose of the analysis.

- (2) In this section—

authorised person means any of the following—

- (a) a category 1 or category 2 researcher;
- (b) a grower;
- (c) a DPI researcher;
- (d) an inspector.

substance means a substance that an authorised person reasonably believes to be any of the following—

- (a) industrial cannabis plants;
- (b) class A or class B research cannabis plants;
- (c) processed cannabis.

[s 25]

25 Family members

- (1) A person who is a member of the immediate family of a licensee is authorised to produce, possess or supply a substance if—
 - (a) the licensee is authorised to produce, possess or supply the substance under the Act; and
 - (b) the person's production, possession or supply of the substance is necessary for, or incidental to the licensee's production, possession or supply of the substance.
- (2) In this section—

substance means any of the following—

- (a) class A research cannabis plants;
- (b) class A research cannabis seed;
- (c) class B research cannabis plants;
- (d) class B research cannabis seed;
- (e) industrial cannabis plants;
- (f) industrial cannabis seed;
- (g) processed cannabis.

26 Employees of authorised persons

- (1) An employee of an authorised person is authorised to produce, possess, supply or transport a substance if—
 - (a) under the Act, the authorised person is authorised to produce, possess, supply or transport the substance; and
 - (b) the employee's production, possession, supply or transportation of the substance is necessary for, or incidental to, performing the employee's employment or engagement.
- (2) In this section—

authorised person means any of the following—

- (a) a licensee;

- (b) a carrier;
- (c) a DPI researcher;
- (d) an inspector;
- (e) a seed supplier;
- (f) a denaturer;
- (g) a manufacturer;
- (h) an analyst.

employee includes agent.

substance means any of the following—

- (a) class A research cannabis plant;
- (b) class A research cannabis seed;
- (c) class B research cannabis plant;
- (d) class B research cannabis seed;
- (e) industrial cannabis plant;
- (f) industrial cannabis seed;
- (g) processed cannabis.

Division 8 Other provisions

27 Recognition as seed supplier

- (1) A person may apply in writing to the chief executive for recognition as a seed supplier.
- (2) The chief executive must recognise the person as a seed supplier if the chief executive is satisfied the person—
 - (a) for trade or commerce, sells or otherwise provides seeds to someone else; and
 - (b) for selling or providing the seed, has a current recognised quality assurance program that conforms to an industry standard or code of practice; and

[s 28]

- (c) is a member of the Queensland Seed Industry Association or a similar organisation in another State.
- (3) The chief executive must give a person recognised as a seed supplier written notice of the recognition.
- (4) The recognition notice must state—
 - (a) the person's recognition number as a seed supplier; and
 - (b) the date the recognition ends, which must not be longer than 3 years after the date of the notice.
- (5) The recognition is not transferable.

28 Licence fees

- (1) The fee payable on application for a licence under the Act, part 5B is \$409.95
- (2) The fee payable on application for the renewal of a licence is \$164.00.

29 Licence conditions—Act, s 64

- (1) The conditions in schedule 8 are prescribed for section 64(3) of the Act.
- (2) Unless otherwise expressly stated, the conditions apply to all licensees.

Part 5 Transitional provisions

30 Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2001

- (1) To remove doubt, it is declared that this regulation, as in force immediately before the commencement of the *Drugs Misuse Amendment Regulation (No. 2) 2001* (the **amending regulation**), continues to apply in relation to an offence

against the Act committed before the commencement of the amending regulation.

- (2) Proceedings for an offence against the Act committed before the commencement of the amending regulation may be continued or started as if the amending regulation had not been made.

31 Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2002

- (1) To remove doubt, it is declared that this regulation, as in force immediately before the commencement of this section, continues to apply in relation to an offence against the Act committed before the commencement of this section.
- (2) Proceedings for an offence against the Act committed before the commencement of this section may be continued or started as if the *Drugs Misuse Amendment Regulation (No. 2) 2002* had not been made.

Schedule 1 Dangerous drugs

sections 4, definition *dangerous drug*, 4A, 5, 6, 8, 8A, 9 and 134 of
the Act

Amphetamine

Cocaine

Heroin

Lysergide

Methylamphetamine

3,4-Methylenedioxymethamphetamine (MDMA)

Paramethoxyamphetamine (PMA)

Paramethoxymethamphetamine (PMMA)

Phencyclidine

Schedule 2 Dangerous drugs

sections 4, definition *dangerous drug*, 4A, 5, 6, 8, 8A, 9 and 134 of the Act

Acetorphine

Acetyl-alpha-methylfentanyl

Acetyldihydrocodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

- (a) in divided preparations containing 100mg or less of acetyldihydrocodeine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of acetyldihydrocodeine.

Acetylmethadol

Acetylmorphine

N-(1-Adamantyl)-1-pentyl-indazole-3-carboxamide (APINACA or AKB48)

Alfentanil

Alkoxyamphetamines and bromo-substituted alkoxyamphetamines other than where separately specified

Alkoxyphenethylamines and alkyl-substituted alkoxyphenethylamines other than where separately specified

Alkylthioamphetamines and substituted alkylthioamphetamines other than where separately specified

Allobarbital

Allylprodine

Alphacetylmethadol

Alphaethyltryptamine

Alphameprodine

Alphamethadol

Schedule 2

Alpha-Methylfentanyl
Alpha-Methylthiofentanyl
Alphamethyltryptamine (AMT)
Alphaprodine
Alpha-Pyrrolidinovalerophenone (alpha-PVP)
Alphenal
Alprazolam
2-Aminoindane
6-(2-Aminopropyl)benzofuran (6-APB)
Aminorex
Amobarbital
Androisoxazole
Androstenediol
Anileridine
Aprobarbital
Atamestane
Bambuterol
Barbital
Barbituric acid and any 5,5 disubstituted derivatives of barbituric acid, whether or not further substituted at position 1 of the ring
Benzethidine
Benzphetamine (N-Benzyl-N-alpha-dimethylphenethylamine)
Benzylmorphine
N-Benzylpiperazine (BZP)
Betacetylmethadol
Beta-Hydroxy-3-methylfentanyl
Beta-Hydroxyfentanyl
Betameprodine

Betamethadol
Betaprodine
Bezitramide
Bolandiol
Bolasterone
Bolazine
Boldenone (dehydrotestosterone)
Bolenol
Bolmantalate
Bromazepam
4-Bromo-2,5-dimethoxyamphetamine (DOB, 4-Bromo-DMA)
4-Bromo-2,5-dimethoxyphenethylamine (2C-B)
Bromo-Dragonfly
(1-(8-bromobenzo[1,2-b;4,5-b']difuran-4-yl)-2-aminopropane)
Brotizolam
Bufotenine (5-Hydroxy-N,N-dimethyltryptamine)
Buprenorphine
Butabarbital
Butalbital
Butallylonal
Butethal
Butorphanol
1-Butyl-3-(2-methoxybenzoyl)indole (RCS-4(C4) 2-methoxy
isomer)
1-Butyl-3-(1-naphthoyl)indole (JWH-073)
Calusterone
Camazepam
Cannabinoids other than tetrahydrocannabinols
Cannabis

Schedule 2

[3-(3-Carbamoylphenyl)phenyl] N-cyclohexylcarbamate (URB-597)
Carfentanil
Catha edulis (Khat)
Cathine
Cathinone
Chlorandrostenolone
Chlordiazepoxide
4-Chloro-2,5-dimethoxyamphetamine (DOC)
4-Chloromethandienone
Chloroxydienone
Chloroxymesterone (dehydrochloromethyltestosterone)
Chlorphentermine (4-chloro-alpha,alpha-dimethylphenethylamine)
Clenbuterol
Clobazam
Clonazepam
Clonitazene
Clorazepate
Clostebol (4-chlorotestosterone)
Clotiazepam
Cloxazolam
Coca leaf
Codeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—
(a) in divided preparations containing 30mg or less of codeine per dosage unit; or
(b) in undivided preparations containing 1% or less of codeine.
Codeine-N-Oxide
Codoxime

4-Cyano-2-dimethylamino-4,4-diphenylbutane

4-Cyano-1-methyl-4-phenylpiperidine

Cyclobarbitol

Cyclohexyl [1,1'-biphenyl]-3-ylcarbamate (URB-602)

Cyclopal

1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (RCS-8)

Danazol

Dehydroepiandrosterone (DHEA)

Delorazepam

Desomorphine

Desoxypipradrol (2-DPMP)

Dextromoramide

Dextropropoxyphene

Diampromide

Diazepam

Diethylpropion

Diethylthiambutene

N,N-Diethyltryptamine

Difenoxin other than in preparations containing 0.5mg or less of difenoxin and a quantity of atropine sulphate equivalent to not less than 5% of the dose of difenoxin per dosage unit

Dihydrocodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

- (a) in divided preparations containing 100mg or less of dihydrocodeine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of dihydrocodeine.

Dihydroetorphine

Dihydrolone

Schedule 2

Dihydromorphine
Dimenoxadol
Dimepheptanol
Dimethandrostanolone
2,5-Dimethoxyamphetamine (2,5-DMA)
2,5-Dimethoxy-4-ethylamphetamine (DOET)
2,5-Dimethoxy-4-ethylphenethylamine (2C-E)
2,5-Dimethoxy-4-ethylthiophenethylamine (2C-T-2)
2,5-Dimethoxy-4-iodoamphetamine (DOI)
2,5-Dimethoxy-4-methylamphetamine (DOM)
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7)
Dimethylamino-1,2-diphenylethane
N,N-Dimethylamphetamine
1,3-Dimethylamylamine (DMAA or methylhexanamine)
3-(1,2-Dimethylheptyl)-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6-H-dibenzo(b,d)pyran
1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210)
N,N-dimethyl-3,4-methylenedioxyamphetamine (MDDM)
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
(cannabicyclohexanol or CP 47, 497 C8 homologue)
Dimethylthiambutene
N,N-Dimethyltryptamine
Dioxaphetyl butyrate
Diphenoxylate other than in preparations containing 2.5mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to not less than 1% of the dose of diphenoxylate per dosage unit
Dipipanone
Drostanolone
Drotebanol

Ecgonine, its esters and derivatives which are convertible to ecgonine and cocaine

Enestebol

Ephedra spp.

Ephedrine

Epitiostanol

Erythropoietin (EPO)

Erythroxyllum coca

Erythroxyllum nova-granatense

Estazolam

Ethchlorvynol

Ethinamate

4-Ethoxyamphetamine

4-Ethoxy-2,5-dimethoxyamphetamine (MEM)

N-Ethylamphetamine

Ethylcathinone (2-ethylamino-1-phenyl-propan-1-one)

Ethyldienolone

Ethylestrenol

Ethyl Loflazepate

Ethylmethylthiambutene

Ethylmorphine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

- (a) in divided preparations containing 100mg or less of ethylmorphine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of ethylmorphine.

N-Ethyl-1-phencyclohexylamine

Etonitazene

Etorphine

Schedule 2

Etoxidine
Etryptamine
Fencamfamin
Fenethylamine (Theophylline-ethylamphetamine)
Fenoterol
Fenproporex (N-2-Cyanoethylamphetamine)
Fentanyl
Fludiazepam
Flunitrazepam
4-Fluoroamphetamine
4-Fluoromethamphetamine
2-Fluoromethcathinone
3-Fluoromethcathinone
4-Fluoromethcathinone
1-(5-Fluoropentyl)-3-(1-adamantylamido)indole (STS-135)
(1-(5-Fluoropentyl)-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)
methanone (XLR-11; 5-Fluoro UR-144)
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694)
1-(5-Fluoropentyl)-3-(4-methyl-1-naphthoyl)indole
(5-Fluoro JWH-122)
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM-2201)
Fluoxymesterone
Flurazepam
Formebolone (formyldienolone)
Formoterol other than in metered aerosols for inhalation
Furazabol
Furethidine
Gamma hydroxybutyric acid (GHB)

Glutethimide
Growth Hormone (hGH)
Halazepam
Haloxazolam
Harmaline
Harmalol
Heptabarbital
Hexethal
Hexobarbital
1-Hexyl-3-(1-naphthoyl)indole (JWH-019)
Hydrocodone
Hydromorphinol
Hydromorphone
N-(2-Hydroxyethyl)-alpha-methylbenzeneethanamine
N-Hydroxy-3,4-methylenedioxyamphetamine (N-Hydroxy-MDA)
4-Hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET)
4-Hydroxy-19-nortestosterone
Hydroxypethidine
Hydroxystenozol
5-Hydroxy tryptophan (5-HTP)
Insulin-like Growth Factor-1 (IGF-1)
4-Iodo-2,5-dimethoxyphenethylamine (2C-I)
Isomethadone
Ketamine
Ketazolam
Ketobemidone
Lefetamine (N,N-Dimethyl-alpha-phenylphenethylamine)
Levomethorphan

Schedule 2

Levophenacylmorphan
Levorphanol
Lophophora (peyote)
Loprazolam
Lorazepam
Lormetazepam
Levomoramide
Lysergamide and N-alkyl derivatives of lysergamide other than lysergide
Lysergic acid
Mazindol
Mebolazine
Mecloqualone (3-(2-Chlorophenyl)-2-methyl-4(3H)-quinazolinone)
Medazepam
Mefenorex (N-(3-Chloropropyl)-alpha-methylphenethylamine)
Mephobarbital
Mepitiostane
Meprobamate
Mesabolone
Mescaline (3,4,5-Trimethoxyphenethylamine)
Mesocarb (3-(Alpha-methylphenethyl)-N-(phenylcarbamoyl)sydnone imine)
Mestanolone (androstalone)
Mesterolone
Metazocine
Methabarbital
Methadone
Methandienone
Methandriol

Methaqualone (2-Methyl-3-(2-methylphenyl)-4(3H)-quinazolinone)
Methcathinone
Methenolone
Methiopropamine
Methoxetamine
5-Methoxy alphanethyltryptamine (5-MeO-AMT)
N-(2-Methoxybenzyl)-2,5-dimethoxy-4-bromophenethylamine
(25B-NBOMe)
N-(2-Methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine
(25C-NBOMe)
N-(2-Methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine
(25I-NBOMe)
5-Methoxy-N,N-diallyltryptamine (5-MeO-DALT)
5-Methoxy dimethyltryptamine
5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT)
5-Methoxy-3,4-methylenedioxyamphetamine (MMDA)
2-(4-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone
(JWH-201)
4-Methoxyphenyl-(1-butyl-1H-indol-3-yl)-methanone (RCS-4 (C4))
2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250)
2-(3-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-302)
Methyl (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-Acetoxy-6a,10b-dimethyl-4,10-dioxo-dodecahydro-2-(3-fur
yl)-2H-naphtho{2,1-c}pyran-7-carboxylate (Salvinorin A)
2-Methylamino-1-(3,4-methylenedioxyphenyl) butane (MBDB)
2-Methylamino-1-phenyl-1-propanone
4-Methylaminorex
Methylclostebol
Methyl-desorphine
Methyldihydromorphine

Schedule 2

5,6-Methylenedioxy-2-aminoindane (MDAI)
3,4-Methylenedioxyamphetamine (MDA)
3,4-Methylenedioxyethylamphetamine (MDEA)
1-(3,4-Methylenedioxy)methcathinone (methydone)
3,4-Methylenedioxypropylamphetamine (MDPV)
4-Methylethylcathinone (4-MEC)
3-Methylfentanyl
2-Methyl-3-morpholino-1, 1-diphenylpropane carboxylic acid
4-Methylmethcathinone
Methylphenidate
Methylphenobarbital
1-[1-(4-Methylphenyl)cyclohexyl]piperidine
1-Methyl-4-phenylpiperidine-4-carboxylic acid
1-[(N-Methylpiperidin-2-yl)methyl]-3-(1-adamantoyl)indole
(AM-1248)
1-[(N-Methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole
(AM-2233)
1-[(N-Methylpiperidin-2-yl)methyl]-3-(4-methyl-1-naphthoyl)indole
(MAM-1220)
1-[(N-Methylpiperidin-2-yl)methyl]-3-(1-naphthoyl)indole
(AM-1220)
N-Methyl-3-piperidyl benzilate
Methyltestosterone
4-Methylthioamphetamine (4-MTA)
3-Methylthiofentanyl
Methyltrienolone
Methyprylon
Metopon
Metribolone

Mibolerone

Midazolam

Mitragyne speciosa (kratom)

Moramide

Morpheridine

Morphine

Morphine methobromide

Morphine-N-oxide

1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)

Myrophine

Nabilone

Nalbuphine

Nalorphine

Nandrolone

Naphthylpyrovalerone (Naphyrone)

Nicocodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

- (a) in divided preparations containing 100mg or less of nicocodine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of nicocodine.

Nicodicodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

- (a) in divided preparations containing 100mg or less of nicodicodine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of nicodicodine.

Nicomorphine

Nimetazepam

Schedule 2

Nitrazepam

Noracymethadol

Norandrostenolone

Norbolethone

Norclostebol

Norcodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

- (a) in divided preparations containing 100mg or less of norcodeine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of norcodeine.

Nordazepam

Norethandrolone

Norlevorphanol

Normethadone

Normethandrone

Normorphine

Norpipanone

Opium

Ovandroton

Oxabolone

Oxandrolone

Oxazepam

Oxazolam

Oxycodone

Oxymesterone

Oxymetholone

Oxymorphone

Papaver bracteatum
Papaver orientale
Papaver somniferum other than the seed thereof which seed has been rendered sterile
Para-Fluorofentanyl
Parahexyl
Pemoline
Pentazocine
Pentobarbital
1-Pentyl-3-(1-adamantoyl)indole (AB-001)
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)
1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210)
(1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144)
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4)
1-Pentyl-3-(2-methoxybenzoyl)indole (RCS-4 (2-methoxy isomer))
1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081)
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)
1-Pentyl-3-(1-naphthoyl)indole (JWH-018)
Pethidine
Phenadoxone
Phenampromide
Phenazepam
Phenazocine
Phendimetrazine
Phenmetrazine
Phenobarbital
Phenomorphane

Phenoperidine

Phentermine (alpha,alpha-Dimethylphenethylamine)

1-(1-Phenylcyclohexyl)pyrrolidine (PCPy)

Phenylmethylbarbituric Acid

1-[1-(Phenylmethyl)cyclohexyl]piperidine

4-Phenylpiperidine-4-carboxylic acid ethyl ester

1-Phenyl-N-propylcyclohexanamine

Pholcodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

- (a) in divided preparations containing 100mg or less of pholcodine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of pholcodine.

Phthalimidopropiophenone

Piminodine

Pinazepam

Pipradol

Piritramide

Prasterone

Pravadoline (WIN 48098)

Prazepam

Probarbital

Proheptazine

Propallylonal

Properidine

Propetandrol

Propiram

Propylhexedrine (1-cyclohexyl-2-methylaminopropane)

1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015)
N-Propyl-3,4-methylenedioxyamphetamine (MDPR)
Psilocin (4-Hydroxy-N,N-dimethyltryptamine)
Psilocybin (O-Phosphoryl-4-hydroxy-N,N-dimethyltryptamine)
Pyrovalerone
Quazepam
Quinbolone
Racemethorphan
Racemoramide
Racemorphan
Remifentanyl
Reproterol
2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol (CP 47,497)
Salbutamol other than in metered aerosols or dry powder or capsules of dry powder for inhalation
Salvia divinorum
Secobarbital
Sigmodal
Silandrone
Somatotropin
Stanolone
Stanozolol
Stenbolone
Sufentanyl
Talbutal
Temazepam
Terbutaline, other than in metered aerosols for inhalation
Testolactone

Schedule 2

Testosterone, other than in implant preparations for growth promotion in animals

Tetrahydrocannabinols including their alkyl homologues other than where separately specified; and their corresponding carboxylic acids

Tetrazepam

Thebacon

Thebaine

Thialbarbital

Thiamylal

1-(1-(2-Thienyl)cyclohexyl)piperidine (TCP)

Thiobarbituric Acid

Thiofentanyl

Thiomesterone (tiomesterone)

Thiopental

Tibolone

Tilidine

Trenbolone (trienbolone, trienolone), other than in implant preparations for use in animals

Trestolone

Triazolam

1-(3-Trifluoromethylphenyl) piperazine (TFMPP)

Trimeperidine

2,4,5-Trimethoxyamphetamine

3,4,5-Trimethoxyamphetamine

Vinbarbital

Vinylbital

Zeranol

Zipeprol (1-(2-Methoxy-2-phenylethyl))-4-(2-hydroxy-3-methoxy-3-phenylpropyl) piperazine

Zolazepam

Zolpidem

Any other anabolic and androgenic steroidal agent

Schedule 3 Specified quantities for particular dangerous drugs

sections 4A, 8, 9, 125 and 134 of the Act

Dangerous drug	Quantity of dangerous drug
Amphetamine	2.0g
Barbituric Acid and any 5,5 disubstituted derivatives of barbituric acid whether or not further substituted at position 1 of the ring	50.0g
4-Bromo-2,5-dimethoxyamphetamine	0.5g
4-Bromo-2,5-dimethoxyphenethylamine	2.0g
Cannabis	500.0g or, if the dangerous drug consists of plants the aggregate weight of which is less than 500.0g, 100 plants
Cocaine	2.0g
Codeine	10.0g
N,N-Diethyltryptamine	2.0g
2,5-Dimethoxy-4-Ethylamphetamine (DOET)	2.0g
2,5-Dimethoxy-4-Methylamphetamine	2.0g
N,N-Dimethyltryptamine	2.0g
Fenethylamine	2.0g
Fentanyl	0.01g
Gamma hydroxybutyric acid	2.0g
Heroin	2.0g
Hydromorphone	2.0g
Lysergide	0.004g
Methadone	2.0g

Dangerous drug	Quantity of dangerous drug
Methcathinone	2.0g
5-Methoxy-3,4-Methylenedioxyamphetamine (MMDA)	2.0g
2-Methylamino-1-(3,4-methylenedioxyphenyl)butane (MBDB)	2.0g
4-Methylaminorex	2.0g
Methylamphetamine	2.0g
3,4-Methylenedioxyethylamphetamine (MDEA)	2.0g
3,4-Methylenedioxymethamphetamine (MDMA)	2.0g
4-Methylthioamphetamine (4-MTA)	2.0g
Moramide	2.0g
Morphine	2.0g
Opium	20.0g
Paramethoxyamphetamine (PMA)	2.0g
Paramethoxymethamphetamine (PMMA)	2.0g
Pethidine	10.0g
Phencyclidine	0.5g
Psilocin	0.10g
Psilocybin	0.10g
Tetrahydrocannabinols including their alkyl homologues except where separately specified; and their corresponding carboxylic acids	2.0g
3,4,5-Trimethoxyamphetamine (TMA)	2.0g

Schedule 4 Specified quantities for particular dangerous drugs

sections 4A, 8, 9 and 134 of the Act

Dangerous drug	Quantity of dangerous drug
Amphetamine	200.0g
Cocaine	200.0g
Heroin	200.0g
Lysergide	0.4g
Methylamphetamine	200.0g
3,4-Methylenedioxymethamphetamine (MDMA)	200.0g
Paramethoxyamphetamine (PMA)	200.0g
Paramethoxymethamphetamine (PMMA)	200.0g
Phencyclidine	50.0g

Schedule 5 Dangerous drugs

sections 4A, 124 and 134 of the Act

Alprazolam
Bromazepam
Brotizolam
Camazepam
Chlordiazepoxide
Clobazam
Clonazepam
Clorazepate
Clotiazepam
Cloxazolam
Delorazepam
Diazepam

Difenoxin other than in preparations containing 0.5mg or less of difenoxin and a quantity of atropine sulphate equivalent to not less than 5% of the dose of difenoxin per dosage unit

Dihydrocodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

- (a) in divided preparations containing 100mg or less of dihydrocodeine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of dihydrocodeine.

Diphenoxylate other than in preparations containing 2.5mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to not less than 1% of the dose of diphenoxylate per dosage unit

Estazolam

Ethyl Loflazepate

Fludiazepam

Flurazepam

Halazepam

Haloxazolam

Ketazolam

Loprazolam

Lorazepam

Lormetazepam

Medazepam

Midazolam

Nimetazepam

Nitrazepam

Nordazepam

Oxazepam

Oxazolam

Pholcodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

- (a) in divided preparations containing 100mg or less of pholcodine per dosage unit; or
- (b) in undivided preparations containing 2.5% or less of pholcodine.

Pinazepam

Prazepam

Quazepam

Temazepam

Tetrazepam

Triazolam

Zolazepam

Schedule 6 Controlled substances

sections 4, definition *controlled substance*, and 134 of the Act

Substance	Alternative name
Acetic anhydride	
N-Acetylanthranilic acid	2-Acetamidobenzoic acid
Allylbenzene	3-Phenyl-1-propene or 2-propenyl benzene
4-Aminobutanoic acid	Piperidinic acid
Ammonium formate	
Anthranilic acid	2-Aminobenzoic acid
Benzaldehyde	
Benzyl bromide	α -Bromotoluene
Benzyl chloride	α -Chlorotoluene
Benzyl cyanide	
Boron tribromide	
Bromobenzene	Phenylbromide
Bromo safrole	
1,4-Butanediol	Tetramethylene glycol
Calcium metal	
1-Chlorophenyl-2-aminopropane	
Chromic acid	
Chromium trioxide	Chromium (VI) oxide
Ephedrine	
Ergometrine	Ergonovine
Ergotamine	
Ethanamine	Monoethylamine
N-Ethylephedrine	
Ethyl phenylacetate	Benzeneacetic acid, ethyl ester
N-Ethylpseudoephedrine	
Formamide	

Substance	Alternative name
Hydriodic acid	Hydrogen iodide solution
Hydrobromic acid	Hydrogen bromide solution
4-Hydroxybutanal	4-Hydroxybutyraldehyde
4-Hydroxybutanoic acid lactone	Gamma-butyrolactone
4-Hydroxybutanoic acid nitrile	4-Hydroxybutyronitrile
4-Hydroxypentanoic acid lactone	Gamma-valerolactone
2-Hydroxytetrahydrofuran	Tetrahydro-2-furanol
Hypophosphorous acid	Phosphinic acid
Iodine	
Isosafrole	5-(1-Propenyl)-1,3-benzodioxole
Lithium aluminium hydride	
Lithium metal	
Mercuric chloride	Mercury bichloride or Mercury (II) chloride
Methylamine	Aminomethane or Monomethylamine
Methylammonium salts	
3,4-Methylenedioxyphenyl-2-propanone	
N-Methylephedrine	
N-Methylformamide	
Methyl phenylacetate	Benzeneacetic acid, methyl ester
N-Methylpseudoephedrine	
Nitroethane	
Norpseudoephedrine	
Palladium	
Phenylacetamide	
Phenylacetic acid	
Phenylacetonitrile	Benzeneacetonitrile, Benzyl cyanide or Benzyl nitrile
Phenylacetyl chloride	
1-Phenyl-2-chloropropane	
1-Phenyl-2-methylaminopropane	

Substance	Alternative name
1-Phenyl-2-nitropropene	
1-Phenyl-2-propanol	
Phenylpropanolamine	Norephedrine
1-Phenyl-1-propanone	Phenyl ethyl ketone or Propiophenone
1-Phenyl-2-propanone	Benzyl methyl ketone or Phenylacetone
1-Phenyl-2-propanone oxime	
Phosphorous acid	Phosphonic Acid
Phosphorus (red or white)	
Piperidine	
Piperonal	Heliotropine or 3,4-Methylenedioxybenzaldehyde
Potassium metal	
Propionic anhydride	
Pseudoephedrine	
Pyridine	
2-Pyrrolidone	Gamma-butyrolactam
Raney nickel	
Safrole	5-(2-Propenyl)-1,3-benzodioxide
Sassafras oil	
Sodium borohydride	
Sodium metal	
Thionyl chloride	
Thorium	

Schedule 7 Conditions for particular persons authorised under part 4

section 10(2)

1 Denaturer

A denaturer must—

- (a) keep industrial cannabis seed that has not been denatured in a securely locked place, other than when removing it to enable it to be denatured; and
- (b) keep records of—
 - (i) the source and quantity of all industrial cannabis seed received for denaturing; and
 - (ii) when and by whom the industrial cannabis seed was delivered to the denaturer; and
- (c) pay the chief executive's reasonable costs of monitoring the denaturer's activities to the extent to which they relate to the denaturing of industrial cannabis seed and the supply of processed cannabis to a manufacturer.

2 DPI researcher

A DPI researcher must—

- (a) keep class A research cannabis plants the researcher is growing securely locked in a glasshouse; and
- (b) grow class B research cannabis plants in an area that is fenced to delineate the area under production; and
- (c) if the chief executive requires the researcher to erect signs indicating the presence of class B research cannabis at a fenced area, ensure the signs are erected as required by the chief executive; and

- (d) keep industrial cannabis seed and class A and class B research cannabis seed in the researcher's possession or under the researcher's control locked in a secure place when not otherwise required—
 - (i) for use for planting; or
 - (ii) to be supplied to another person; and
- (e) keep a register that includes the following information—
 - (i) the varieties or strains of cannabis plants and cannabis seed under the researcher's control;
 - (ii) the source, quantity and delivery details for cannabis seed and plant varieties the researcher receives;
 - (iii) how, when and from whom the researcher received cannabis plants and seed delivered to the researcher;
 - (iv) if a carrier delivered the cannabis plants or seed to the researcher, the name of the person who delivered the plants or seed;
 - (v) if a researcher engages a carrier to deliver cannabis plants or seed to someone else—
 - (A) the name of the person to whom the plants or seed were given for delivery; and
 - (B) the name of the person to whom it is intended the plants or seed be supplied by the researcher.

3 Inspector

An inspector who possesses industrial cannabis plants or seed or class A or class B research cannabis plants or seed for supplying them to someone else under part 4 must keep the plants or seed in a secure place until the inspector supplies them to the person.

4 Seed supplier

A seed supplier must—

- (a) keep industrial cannabis seed in the supplier's possession or under the supplier's control locked in a secure place when not otherwise required for use for lawfully supplying the seed to a person mentioned in section 20; and
- (b) keep records of the following information—
 - (i) the source and quantity of all industrial cannabis seed supplied to the supplier;
 - (ii) how, when and by whom industrial cannabis seed was delivered to the supplier;
 - (iii) if industrial cannabis seed is delivered to the supplier by a carrier—the name of the person who actually delivered the seed;
 - (iv) if the supplier supplies industrial cannabis seed to a carrier for delivery to a person—
 - (A) the name of the person to whom the seed was given for delivery; and
 - (B) the name of the person to whom it is intended the seed be supplied by the supplier;
 - (v) the name of each person to whom the supplier supplies industrial cannabis seed; and
- (c) ensure all industrial cannabis seed received by the seed supplier is labelled to indicate—
 - (i) if the seed is cannabis seed harvested from an industrial cannabis plant—that fact; or
 - (ii) if the seed is certified cannabis seed—that fact; and
- (d) ensure that each package of certified cannabis seed supplied by the seed supplier has a label on it, or attached to it, that describes the contents of the package as certified cannabis seed; and

- (e) pack all industrial cannabis seed to be delivered to someone else by a carrier in a way that ensures, as far as reasonably practicable, seed can not be lost if the package is damaged.

5 Analyst

- (1) This section applies if an analyst is engaged or employed to analyse a substance to determine its THC concentration.
- (2) The analyst must analyse the substance in a laboratory whose functions and operations are accredited by NATA for competence to undertake drug analysis.
- (3) The analyst must keep standard THC material in a securely locked place other than when the analyst is using the material in analysing the substance to determine its THC concentration.
- (4) The analyst must keep the substance in a securely locked place other than when the analyst is analysing the substance.
- (5) In this section—

NATA means the National Association of Testing Authorities, Australia ABN 59 004 379 748.

substance means a substance the analyst reasonably believes to be any of the following—

- (a) industrial cannabis plants;
- (b) class A or class B research cannabis plants;
- (c) processed cannabis.

Schedule 8 Licence conditions

section 29(1)

- 1 A licensee who is authorised to produce class A research cannabis must—
 - (a) grow the cannabis in a glasshouse that is capable of being securely locked; and
 - (b) keep the glasshouse securely locked other than when the licensee or a person authorised by the licensee is performing functions directly associated with growing cannabis in the glasshouse.
- 2 A licensee who is authorised to produce class B research cannabis must—
 - (a) grow the cannabis in an area that is fenced to delineate the area under production; and
 - (b) if the chief executive requires the licensee to erect signs indicating the presence of class B research cannabis at a fenced area, ensure the signs are erected as required by the chief executive.
- 3 A licensee must keep cannabis seed in the licensee's possession in a securely locked place, other than when the licensee uses the seed for a purpose that is authorised under the licensee's licence.
- 4 A licensee must keep a register of the following—
 - (a) the strains or varieties of cannabis seed in the licensee's possession;
 - (b) the strains or varieties of cannabis plants the licensee is growing.
- 5 A licensee must keep records of the following information—
 - (a) the source and quantity of all cannabis plants and seed supplied to the licensee;

- (b) how, when and by whom plants or seed were delivered to the licensee;
 - (c) if cannabis plants or seed are delivered to the licensee by a carrier—the name of the person who actually delivered the plants or seed;
 - (d) if cannabis plants or seed are supplied to a carrier for delivery to a person—
 - (i) the name of the person to whom the plants or seed were given for delivery; and
 - (ii) the name of the person to whom it is intended the plants or seed be supplied by the carrier.
- 6 As soon as reasonably practicable after a licensee receives a package containing cannabis plants or seed that appears to have been tampered with, the licensee must inform an inspector or a police officer that the package appears to have been tampered with.
- 7 A licensee must pay the chief executive's reasonable costs of monitoring activities performed under the licence, including any costs of an analyst conducting a laboratory analysis necessary to determine the concentration of THC in the leaves and flowering heads of cannabis plants in the licensee's possession.
- 8 A category 2 researcher must allow an inspector to destroy, or supervise the destruction of, cannabis plants in the possession of the licensee that have been found, by an analyst conducting a laboratory analysis of a random sample of the leaves and flowering heads of the plants, to have a concentration of THC in their leaves and flowering heads of 3% or more.
- 9 A grower must allow an inspector to destroy, or supervise the destruction of, cannabis plants in the possession of the licensee that have been found, by an analyst conducting a laboratory analysis of a random sample of the leaves and flowering heads of the plants, to have a THC concentration in their leaves and flowering heads of more than 1%.
- 10 A licensee who proposes to supply industrial cannabis seed for sale by wholesale or retail must ensure—

- (a) if the seed is cannabis seed harvested from an industrial cannabis plant—the package containing the seed has a label on it or attached to it that describes the contents of the package as cannabis seed harvested from an industrial cannabis plant; or
 - (b) if the seed is certified cannabis seed—the package containing the seed has a label on it, or attached to it, that describes the contents of the package as certified cannabis seed.
- 11 A category 2 researcher must ensure, as far as practicable, that cannabis seed supplied to the researcher by a person in another State or a foreign country is certified as seed that, if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads of less than 3%.
- 12 A grower must ensure, as far as practicable, that cannabis seed supplied to the grower by a person in another State or a foreign country is certified as seed that, if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads of not more than 0.5%.

Schedule 8A Gross weight of relevant substances for ss 9A, 9B, 9C and 9D of Act

sections 9A, 9B, 9C, 9D and 134 of the Act

Part 1 Substances that include their salts, derivatives and stereo-isomers

- 1 In this part, a reference to a substance includes a reference to—
 - (a) a salt, derivative or stereo-isomer of the substance; and
 - (b) a salt of a derivative or stereo-isomer of the substance.

Substance	Alternative name	Gross weight
N-Acetylanthranilic acid	2-Acetamidobenzoic acid	0.1g
Allylbenzene	3-Phenyl-1-propene or 2-propenyl benzene	0.1g
4-Aminobutanoic acid	Piperidinic acid	0.1g
Ammonium formate		0.1g
Anthranilic acid	2-Aminobenzoic acid	0.1g
Benzaldehyde		0.1g

Substance	Alternative name	Gross weight
Benzyl bromide	α -Bromotoluene	0.1g
Benzyl chloride	α -Chlorotoluene	0.1g
Benzyl cyanide		0.1g
Boron tribromide		0.1g
Bromobenzene	Phenylbromide	0.1g
Bromo safrole		0.1g
1,4-Butanediol	Tetramethylene glycol	0.1g
1-Chlorophenyl-2-aminopropane		0.1g
Chromic acid		0.1g
Chromium trioxide	Chromium (VI) oxide	0.1g
Ephedrine		0.1g
Ergometrine	Ergonovine	0.1g
Ergotamine		0.1g
Ethanamine	Monoethylamine	0.1g
N-Ethylephedrine		0.1g
Ethyl phenylacetate	Benzeneacetic acid, ethyl ester	0.1g
N-Ethylpseudoephedrine		0.1g
Formamide		0.1g
4-Hydroxybutanal	4-Hydroxybutyraldehyde	0.1g
4-Hydroxybutanoic acid lactone	Gamma-butyrolactone	0.1g

Substance	Alternative name	Gross weight
4-Hydroxybutanoic acid nitrile	4-Hydroxybutyronitrile	0.1g
4-Hydroxypentanoic acid lactone	Gamma-valerolactone	0.1g
2-Hydroxytetrahydrofuran	Tetrahydro-2-furanol	0.1g
Hypophosphorous acid	Phosphinic acid	0.1g
Isosafrole	5-(1-Propenyl)-1,3-benzodioxole	0.1g
Lithium aluminium hydride		0.1g
Mercuric chloride	Mercury bichloride or Mercury (II) chloride	0.1g
Methylamine	Aminomethane or Monomethylamine	0.1g
Methylammonium salts		0.1g
3,4-Methylenedioxyphenyl-2-propanone		0.1g
N-Methylephedrine		0.1g
N-Methylformamide		0.1g
Methyl phenylacetate	Benzenecetic acid, methyl ester	0.1g
N-Methylpseudoephedrine		0.1g
Nitroethane		0.1g
Norpseudoephedrine		0.1g
Palladium		0.1g
Phenylacetamide		0.1g
Phenylacetic acid		0.1g

Substance	Alternative name	Gross weight
Phenylacetone	Benzeneacetone, Phenyl cyanide or Benzyl nitrile	0.1g
Phenylacetone hydrochloride		0.1g
1-Phenyl-2-chloropropane		0.1g
1-Phenyl-2-methylaminopropane		0.1g
1-Phenyl-2-nitropropene		0.1g
1-Phenyl-2-propanol		0.1g
Phenylpropanolamine	Norephedrine	0.1g
1-Phenyl-1-propanone	Phenyl ethyl ketone or Propiophenone	0.1g
1-Phenyl-2-propanone	Benzyl methyl ketone or Phenylacetone	0.1g
1-Phenyl-2-propanone oxime		0.1g
Piperidine		0.1g
Piperonal	Heliotropine or 3,4-Methylenedioxybenzaldehyde	0.1g
Propionic anhydride		0.1g
Pseudoephedrine		50g or 1L
Pyridine		0.1g
2-Pyridolone	Gamma-butyrolactam	0.1g
Raney nickel		0.1g
Safrole	5-(2-Propenyl)-1,3-benzodioxole	0.1g

Substance	Alternative name	Gross weight
Sassafras oil		0.1g
Sodium borohydride		0.1g
Thionyl chloride		0.1g
Thorium		0.1g

Part 2
Substances that do not include their salts, derivatives and stereo-isomers

- 2 In this part, a reference to a substance does not include a reference to—
- (a) a salt, derivative or stereo-isomer of the substance; and
 - (b) a salt of a derivative or stereo-isomer of the substance.

Substance	Alternative name	Gross weight
Acetic anhydride		0.1g
Calcium metal		0.1g
Hydriodic acid	Hydrogen iodide solution	0.1g
Hydrobromic acid	Hydrogen bromide solution	0.1g

Substance	Alternative name	Gross weight
Iodine		0.1g
Lithium metal		25g
Phosphorous acid	Phosphonic Acid	0.1g
Phosphorus (red or white)		0.1g
Potassium metal		0.1g
Sodium metal		0.1g

**Schedule 8B Things specified for ss 9A, 9B,
9C and 9D, and prescribed
for s 134, of Act**

sections 9A, 9B, 9C, 9D and 134 of the Act

- 1 condenser
- 2 distillation head
- 3 heating mantle
- 4 manual or mechanical pill press, including a pill press under repair, a modification of a pill press and parts for a pill press
- 5 reaction vessel, including a reaction vessel under repair or a modification of a reaction vessel
- 6 rotary evaporator
- 7 splash head, including a splash head under repair or parts for a splash head

Schedule 8C Prohibited combinations of items

sections 10B and 134 of the Act

- 1 A combination consisting of substances that are or contain—
 - (a) pseudoephedrine or its salts; and
 - (b) hypophosphorous acid; and
 - (c) iodine.
- 2 A combination consisting of substances that are or contain—
 - (a) pseudoephedrine or its salts; and
 - (b) hydriodic acid; and
 - (c) phosphorous (red or white).
- 3 A combination consisting of substances that are or contain—
 - (a) pseudoephedrine or its salts; and
 - (b) lithium metal; and
 - (c) ammonia gas.

Schedule 8D Relevant dangerous drugs

sections 131 and 134 of the Act

amphetamine

methamphetamine

Schedule 9 Dictionary

section 2

analyst means a person who holds an approval under the *Health (Drugs and Poisons) Regulation 1996* to obtain, possess and use standard THC material to calibrate an analytical instrument used for analysing a substance to determine its THC concentration.

carrier means a person who carries on a business of transporting a thing for delivery to the person to whom it is consigned, whether in Queensland or elsewhere, and whether the thing is transported by air, rail, road or sea.

condenser means a cooling device for converting gases or vapours to liquid or solid form.

consigned includes addressed.

consigned cannabis means any of the following—

- (a) industrial cannabis plants;
- (b) industrial cannabis seed;
- (c) class A research cannabis;
- (d) class B research cannabis;
- (e) processed cannabis.

distillation head means an apparatus that—

- (a) fits on top of a reaction vessel or a vessel that serves the same purpose as a reaction vessel; and
- (b) connects to a condenser; and
- (c) is suitably angled to allow vapour to flow downwards into a collection vessel.

DPI researcher means a public service officer—

- (a) who is employed in the department within which the *Agricultural Standards Act 1994* is administered; and

- (b) whose duties include plant breeding; and
- (c) who is authorised by the chief executive in writing to perform activities stated in part 4, division 4.

heating mantle means a device designed or adapted to heat a reaction vessel or a vessel that serves the same purpose as a reaction vessel.

seed supplier means a person recognised as a seed supplier under section 27.

splash head means an apparatus that fits between a reaction vessel, or a vessel that serves the same purpose as a reaction vessel, and a condenser and stops a heated substance contaminating the distillate.

standard THC material means THC of a known purity.

supply—

- (a) for part 3, see section 43A of the Act; or
- (b) for part 4, does not include administer.

Endnotes

1 Index to endnotes

	Page
2	Date to which amendments incorporated.69
3	Key69
4	Table of reprints70
5	List of legislation71
6	List of annotations75

2 Date to which amendments incorporated

This is the reprint date mentioned in the *Reprints Act 1992*, section 5(c). Accordingly, this reprint includes all amendments that commenced operation on or before 1 July 2013. Future amendments of the *Drugs Misuse Regulation 1987* may be made in accordance with this reprint under the *Reprints Act 1992*, section 49.

3 Key

Key to abbreviations in list of legislation and annotations

Key	Explanation	Key	Explanation
AIA	= Acts Interpretation Act 1954	(prev)	= previously
amd	= amended	proc	= proclamation
amdt	= amendment	prov	= provision
ch	= chapter	pt	= part
def	= definition	pubd	= published
div	= division	R[X]	= Reprint No. [X]
exp	= expires/expired	RA	= Reprints Act 1992
gaz	= gazette	reloc	= relocated
hdg	= heading	renum	= renumbered
ins	= inserted	rep	= repealed
lap	= lapsed	(retro)	= retrospectively
notfd	= notified	rv	= revised version
num	= numbered	s	= section
o in c	= order in council	sch	= schedule
om	= omitted	sdiv	= subdivision
orig	= original	SIA	= Statutory Instruments Act 1992
p	= page	SIR	= Statutory Instruments Regulation 2002
para	= paragraph	SL	= subordinate legislation
prec	= preceding	sub	= substituted
pres	= present	unnum	= unnumbered
prev	= previous		

4 Table of reprints

A new reprint of the legislation is prepared by the Office of the Queensland Parliamentary Counsel each time a change to the legislation takes effect.

The notes column for this reprint gives details of any discretionary editorial powers under the *Reprints Act 1992* used by the Office of the Queensland Parliamentary Counsel in preparing it. Section 5(c) and (d) of the Act are not mentioned as they contain mandatory requirements that all amendments be included and all necessary consequential amendments be incorporated, whether of punctuation, numbering or another kind. Further details of the use of any discretionary editorial power noted in the table can be obtained by contacting the Office of the Queensland Parliamentary Counsel by telephone on 3237 0466 or email legislation.queries@oqpc.qld.gov.au.

From 29 January 2013, all Queensland reprints are dated and authorised by the Parliamentary Counsel. The previous numbering system and distinctions between printed and electronic reprints is not continued with the relevant details for historical reprints included in this table.

Reprint No.	Amendments to	Effective	Reprint date
1	reg pubd gaz 6 May 1989	6 May 1989	23 April 1993
2	1996 SL No. 309	8 November 1996	4 December 1996
2A	1997 SL No. 303	19 September 1997	21 November 1997
2B	1997 SL No. 459	19 December 1997	14 August 1998
3	1998 SL No. 348	18 December 1998	5 February 1999
3A	1999 SL No. 41	26 March 1999	8 April 1999
3B	1999 SL No. 235	22 October 1999	2 December 1999
3C	2000 Act No. 28	27 July 2000	11 August 2000
3D	2000 SL No. 234	8 September 2000	15 September 2000
3E	2001 SL No. 52	25 May 2001	8 June 2001
4	2001 SL No. 174	21 September 2001	5 October 2001
4A	2001 SL No. 249	7 December 2001	14 December 2001
Reprint No.	Amendments included	Effective	Notes
4B	2002 SL No. 255	27 September 2002	
4C	2002 SL No. 368	20 December 2002	
4D	2003 SL No. 374	19 December 2003	
4E	2004 SL No. 231	29 November 2004	
4F	2005 SL No. 7	11 February 2005	
4G	2005 SL No. 268	11 December 2005	
4H	2006 SL No. 71	27 April 2006	
5	2006 SL No. 267	4 December 2006	
5A	2007 SL No. 232	29 October 2007	
5B	2008 Act No. 4	1 June 2008	
	2008 SL No. 144		
5C	2008 SL No. 314	19 September 2008	R5C withdrawn, see R6
6	—	19 September 2008	
6A	2009 SL No. 99	19 June 2009	

Reprint No.	Amendments included	Effective	Notes
6B	2009 SL No. 176	28 August 2009	
6C	2010 SL No. 268	1 October 2010	
6D	2011 SL No. 110	1 July 2011	
6E	2011 SL No. 168	9 September 2011	
6F	2011 SL No. 222	11 November 2011	R6F withdrawn, see R7
7	—	11 November 2011	
7A rv	2012 SL No. 92	1 July 2012	

Current as at	Amendments included	Notes
5 April 2013	2013 SL No. 41	
29 April 2013	2013 Act No. 14	
1 July 2013	2013 SL No. 102	

5 List of legislation

Regulatory impact statements

For subordinate legislation that has a regulatory impact statement, specific reference to the statement is included in this list.

Explanatory notes

All subordinate legislation made on or after 1 January 2011 has an explanatory note. For subordinate legislation made before 1 January 2011 that has an explanatory note, specific reference to the note is included in this list.

Drugs Misuse Regulation 1987

made by the Administrator of the Government on 29 October 1987

pubd gaz 31 October 1987 pp 836–47

commenced 31 October 1987 (see s 2)

exempted from application of SIA pt 7 (see SIA sch 2A)

Notes—(1) This regulation contains provisions relocated from the Drugs Misuse Act 1986.

(2) A list of legislation for the relocated provisions of the Drugs Misuse Act 1986 appears below.

amending legislation—

regulations published gazette (pre SL series)—

17 December 1988 pp 2214–15

commenced on date of publication

6 May 1989 pp 230–1

commenced 6 May 1989 (see s 2)

Drugs Misuse Amendment Regulation (No. 1) 1996 SL No. 309

notfd gaz 8 November 1996 pp 959–61

ss 1–2 commenced on date of notification

remaining provisions commenced 8 November 1996 (see s 2)

List of legislation to Drugs Misuse Act 1986 No. 36 schs 1–6—before relocation to Drugs Misuse Regulation 1987 as schs 1–6 (see 1996 No. 49 s 21)—

Original relocated Act

Drugs Misuse Act 1986 No. 36 schs 1–6

date of assent 5 September 1986

ss 1–2 commenced on date of assent

remaining provisions commenced 27 October 1986 (proc pubd gaz 25 October 1986 p 1242)

amending legislation—

Drugs Misuse Act Amendment Act 1987 No. 53

date of assent 1 October 1987

ss 1–2 commenced on date of assent

s 10(a)(iii) commenced 6 May 1989 (proc pubd gaz 6 May 1989 p 213)

remaining provisions commenced 31 October 1987 (proc pubd gaz 31 October 1987 p 819)

Drugs Misuse Act Amendment Act 1989 No. 34

date of assent 28 April 1989

ss 1–2 commenced on date of assent

remaining provisions commenced 6 May 1989 (proc pubd gaz 6 May 1989 p 213)

Statute Law (Miscellaneous Provisions) Act 1990 No. 88 s 3 sch

date of assent 6 December 1990

commenced on date of assent

Drugs Misuse Amendment Act 1995 No. 18

date of assent 11 April 1995

ss 1–2 commenced on date of assent

s 6 commenced 8 December 1995 (1995 SL No. 358)

remaining provisions commenced 12 April 1996 (automatic commencement under AIA s 15DA(2))

Drugs Misuse Amendment Act 1996 No. 49 ss 1, 15–21

date of assent 15 November 1996

commenced on date of assent

List of legislation to Drugs Misuse Regulation 1987—after relocation of Drugs Misuse Act 1986 No. 36 schs 1–6

Drugs Misuse Amendment Regulation (No. 1) 1997 SL No. 303

notfd gaz 19 September 1997 pp 262–3

commenced on date of notification

Drugs Misuse Amendment Regulation (No. 2) 1997 SL No. 459

notfd gaz 19 December 1997 pp 1770–7

commenced on date of notification

Drugs Misuse Amendment Regulation (No. 1) 1998 SL No. 348

notfd gaz 18 December 1998 pp 1551–7

commenced on date of notification

Drugs Misuse Amendment Regulation (No. 1) 1999 SL No. 41

notfd gaz 26 March 1999 pp 1450–3

commenced on date of notification

Drugs Misuse Amendment Regulation (No. 2) 1999 SL No. 235

notfd gaz 22 October 1999 pp 710–11

commenced on date of notification

Drugs Misuse Amendment Act 2000 No. 28 pt 1 s 26 sch

date of assent 27 July 2000

commenced on date of assent

Drugs Misuse Amendment Regulation (No. 1) 2000 SL No. 234

notfd gaz 8 September 2000 pp 134–5

commenced on date of notification

Drugs Misuse Amendment Regulation (No. 1) 2001 SL No. 52

notfd gaz 25 May 2001 pp 334–6

commenced on date of notification

Drugs Misuse Amendment Regulation (No. 2) 2001 SL No. 174

notfd gaz 21 September 2001 pp 230–1

commenced on date of notification

Drugs Misuse Amendment Regulation (No. 3) 2001 SL No. 249

notfd gaz 7 December 2001 pp 1270–1

commenced on date of notification

Drugs Misuse Amendment Regulation (No. 1) 2002 SL No. 255

notfd gaz 27 September 2002 pp 340–4

commenced on date of notification

Drugs Misuse Amendment Regulation (No. 2) 2002 SL No. 368

notfd gaz 20 December 2002 pp 1359–63

commenced on date of notification

Drugs Misuse Amendment Regulation (No. 1) 2003 SL No. 374

notfd gaz 19 December 2003 pp 1307–13

commenced on date of notification

**Primary Industries Legislation Amendment Regulation (No. 1) 2004 SL No. 231 pts
1, 7**

notfd gaz 29 October 2004 pp 734–7

ss 1–2 commenced on date of notification

remaining provisions commenced 29 November 2004 (see s 2)

Drugs Misuse Amendment Regulation (No. 1) 2005 SL No. 7

notfd gaz 11 February 2005 pp 515–16

commenced on date of notification

Primary Industries Legislation Amendment Regulation (No. 1) 2005 SL No. 268 pts 1, 7

notfd gaz 11 November 2005 pp 955–7
ss 1–2 commenced on date of notification
remaining provisions commenced 11 December 2005 (see s 2)

Drugs Misuse Amendment Regulation (No. 1) 2006 SL No. 71

notfd gaz 21 April 2006 pp 1544–5
ss 1–2 commenced on date of notification
remaining provisions commenced 27 April 2006 (see s 2)

Primary Industries Legislation Amendment Regulation (No. 1) 2006 SL No. 267 pts 1, 7

notfd gaz 3 November 2006 pp 1103–4
ss 1–2 commenced on date of notification
remaining provisions commenced 4 December 2006 (see s 2)

Primary Industries Legislation Amendment Regulation (No. 2) 2007 SL No. 232 ss 1–2(1), pt 7

notfd gaz 21 September 2007 pp 447–9
ss 1–2 commenced on date of notification
remaining provisions commenced 29 October 2007 (see s 2(1))

Drugs Misuse Amendment Act 2008 No. 4 pts 1, 3

date of assent 20 February 2008
ss 1–2 commenced on date of assent
remaining provisions commenced 1 June 2008 (2008 SL No. 143)

Drugs Misuse Amendment Regulation (No. 1) 2008 SL No. 144

notfd gaz 30 May 2008 pp 674–6
ss 1–2 commenced on date of notification
remaining provisions commenced 1 June 2008 (see s 2)

Primary Industries and Fisheries Legislation Amendment Regulation (No. 1) 2008 SL No. 314 s 1, pt 7

notfd gaz 19 September 2008 pp 407–9
commenced on date of notification

Drugs Misuse Amendment Regulation (No. 1) 2009 SL No. 99

notfd gaz 19 June 2009 pp 707–11
commenced on date of notification

Primary Industries and Fisheries Legislation Amendment Regulation (No. 2) 2009 SL No. 176 pts 1, 7

notfd gaz 28 August 2009 pp 1491–6
commenced on date of notification

Primary Industries and Fisheries Legislation Amendment Regulation (No. 1) 2010 SL No. 268 pts 1, 4

notfd gaz 1 October 2010 pp 294–7
commenced on date of notification

Employment, Economic Development and Innovation Legislation Amendment Regulation (No. 1) 2011 SL No. 110 pts 1, 7

notfd gaz 24 June 2011 pp 534–8
 ss 1–2 commenced on date of notification
 remaining provisions commenced 1 July 2011 (see s 2)

Drugs Misuse Amendment Regulation (No. 1) 2011 SL No. 168

notfd gaz 9 September 2011 pp 100–3
 commenced on date of notification

Drugs Misuse Amendment Regulation (No. 2) 2011 SL No. 222

notfd gaz 11 November 2011 pp 495–6
 commenced on date of notification

Agriculture and Fisheries Legislation Amendment Regulation (No. 1) 2012 SL No. 92 pts 1, 8

notfd gaz 29 June 2012 pp 704–10
 ss 1–2 commenced on date of notification
 remaining provisions commenced 1 July 2012 (see s 2)

Drugs Misuse Amendment Regulation (No. 1) 2013 SL No. 41

notfd gaz 5 April 2013 pp 490–1
 commenced on date of notification

Criminal Law (Child Exploitation and Dangerous Drugs) Amendment Act 2013 No. 14 pts 1, 6

date of assent 29 April 2013
 commenced on date of assent

Agriculture and Fisheries Legislation Amendment Regulation (No. 1) 2013 SL No. 102 pts 1, 8

notfd gaz 21 June 2013 pp 503–7
 ss 1–2 commenced on date of notification
 remaining provisions commenced 1 July 2013 (see s 2)

6 List of annotations

PART 1—PRELIMINARY

pt hdg ins 1996 SL No. 309 s 4

Dictionary

prov hdg pres s 2 hdg sub 1996 SL No. 309 s 5(1)

s 2 prev s 2 om R2 (see RA s 37)

pres s 2 (prev s 4) sub 1998 SL No. 348 s 3(2)

renum 2002 No. 255 s 3

def *occupier's notice* reloc to sch 9 1998 SL No. 348 s 3(1)

def *record of proceedings* reloc to sch 9 1998 SL No. 348 s 3(1)

def *search warrant* reloc to sch 9 1998 SL No. 348 s 3(1)

def *supply* ins 1996 SL No. 309 s 5(3)

om 1998 SL No. 348 s 3(2)

def *the Act* sub 1989 reg pubd gaz 6 May 1989 pp 230–1
om 1996 SL No. 309 s 5(2)

PART 2—SYRINGES AND DANGEROUS DRUGS DISPOSAL PROCEDURES

pt hdg prev pt 2 hdg ins 1996 SL No. 309 s 6
om 2002 SL No. 255 s 4
pres pt 2 hdg (prev pt 3 hdg) ins 1996 SL No. 309 s 11
renum 2002 SL No. 255 s 5(1)

Prescribed procedures for the disposal of hypodermic syringes and needles

s 3 prev s 3 om R1 (see RA s 40)
pres s 3 (prev s 9) ins reg pubd gaz 6 May 1989 pp 230–1
renum 2002 SL No. 255 s 5(2)
amd 2009 SL No. 99 s 3

Prescribed procedure for disposal of dangerous drugs

s 4 (prev s 10) ins reg pubd gaz 6 May 1989 pp 230–1
renum 2002 SL No. 255 s 5(2)
amd 2006 SL No. 71 s 4; 2008 Act No. 4 s 34; 2009 SL No. 99 s 4

PART 3—CONTROLLED SUBSTANCES

pt hdg (prev pt 4 hdg) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5(1)

Other act that is a relevant transaction—Act, s 43C(b)

s 5 prev s 5 amd 1996 SL No. 309 s 7
om 2002 SL No. 255 s 4
pres s 5 (prev s 11) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5(2)

Documents and proof of identity required for supply of a controlled substance or controlled thing—Act, s 43D(1)(a)

prov hdg amd 2008 Act No. 4 s 35(1)
s 6 prev s 6 amd 1996 SL No. 309 s 8
om 2002 SL No. 255 s 4
pres s 6 (prev s 12) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5(2)
amd 2008 Act No. 4 s 35(2)–(4); 2009 SL No. 99 s 5

End user declaration to be given to commissioner of police service—Act, s 43D(1)(d)

s 6A ins 2008 Act No. 4 s 36

Details about supply of controlled substance or controlled thing to be recorded in register

prov hdg amd 2008 Act No. 4 s 37(1)
s 7 prev s 7 sub reg pubd gaz 17 December 1988 pp 2214–15
amd 1996 SL No. 309 s 9
om 2002 SL No. 255 s 4
pres s 7 (prev s 13) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5(2)
amd 2008 Act No. 4 s 37(2)–(4); 2012 SL No. 92 s 19

Details about loss or theft of controlled substance or controlled thing to be recorded in register

prov hdg amd 2008 Act No. 4 s 38(1)
s 8 prev s 8 om 1996 SL No. 309 s 10
pres s 8 (prev s 14) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5(2)
amd 2008 Act No. 4 s 38

Keeping of register, invoice and other documents

s 9 (prev s 15) ins 1996 SL No. 309 s 12
renum 2002 SL No. 255 s 5(2)
amd 2008 Act No. 4 s 39

PART 4—COMMERCIAL PRODUCTION OF INDUSTRIAL CANNABIS

pt hdg (prev pt 5 hdg) ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Division 1—Preliminary

div hdg ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Operation of pt 4 and schs 7 and 8

s 10 ins 2002 SL No. 255 s 6
amd 2012 SL No. 92 s 20

Division 2—Certified cannabis seed

div hdg ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Certifying cannabis seed

s 11 ins 2002 SL No. 255 s 6

Division 3—Carriers

div hdg ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Application of div 3

s 12 ins 2002 SL No. 255 s 6

Supply

s 13 ins 2002 SL No. 255 s 6

Possession

s 14 ins 2002 SL No. 255 s 6

Division 4—DPI researchers

div hdg ins 2002 SL No. 255 s 6

Supply

s 15 ins 2002 SL No. 255 s 6

Production

s 16 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Endnotes

Possession

s 17 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Division 5—Inspectors

div hdg ins 2002 SL No. 255 s 6

Supply

s 18 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Possession

s 19 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Division 6—Seed suppliers

div hdg ins 2002 SL No. 255 s 6

Supply

s 20 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Possession

s 21 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Division 7—Other persons

div hdg ins 2002 SL No. 255 s 6

Denaturer

s 22 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Manufacturer

s 23 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Analyst

s 24 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Family members

s 25 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Employees of authorised persons

s 26 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Division 8—Other provisions

div hdg ins 2002 SL No. 255 s 6

Recognition as seed supplier

s 27 ins 1998 SL No. 348 s 4
sub 2002 SL No. 255 s 6

Licence fees

- s 28** ins 1998 SL No. 348 s 4
 sub 2002 SL No. 255 s 6
 amd 2004 SL No. 231 s 14; 2005 SL No. 268 s 14; 2006 SL No. 267 s 14;
 2007 SL No. 232 s 14; 2008 SL No. 314 s 14; 2009 SL No. 176 s 17; 2010
 SL No. 268 s 7; 2011 SL No. 110 s 14; 2012 SL No. 92 s 21; 2013 SL No.
 102 s 16

Licence conditions—Act, s 64

- s 29** ins 2001 SL No. 52 s 3
 sub 2002 SL No. 255 s 6

PART 5—TRANSITIONAL PROVISIONS

- pt hdg** (prev pt 6 hdg) ins 2001 SL No. 174 s 3
 renum 2002 SL No. 255 s 5(1)
 amd 2002 SL No. 368 s 3

Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2001

- s 30** ins 2001 SL No. 174 s 3

Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2002

- s 31** ins 2002 SL No. 368 s 4

SCHEDULE

amd reg pubd gaz 17 December 1988 pp 2214–5
 om 1996 SL No. 309 s 13

SCHEDULE 1—DANGEROUS DRUGS

- sch hdg** ins 1997 SL No. 459 s 3(1)
 amd 2009 SL No. 99 s 6; 2013 SL No. 41 s 3(1)
- sch 1** (prev 1986 Act No. 36 sch 1)
 amd 1996 Act No. 49 s 15
 reloc 1996 Act No. 49 s 21
 amd 1997 SL No. 459 s 3(2); 2001 SL No. 174 s 4; 2002 SL No. 255 s 7(1);
 2008 Act No. 4 s 40; 2013 SL No. 41 s 3(2)

SCHEDULE 2—DANGEROUS DRUGS

- sch hdg** ins 1997 SL No. 459 s 4(1)
 amd 2009 SL No. 99 s 6; 2013 SL No. 41 s 4(1)
- sch 2** (prev 1986 Act No. 36 sch 2)
 amd 1987 Act No. 53 s 11; 1989 Act No. 34 s 22; 1996 Act No. 49 s 16
 reloc 1996 Act No. 49 s 21
 amd 1997 SL No. 303 s 3; 1997 SL No. 459 s 4(2)–(3); 1999 SL No. 41 s 3;
 2001 SL No. 174 s 5; 2001 SL No. 249 s 3; 2002 SL No. 255 s 7(1); 2002
 SL No. 368 s 5; 2003 SL No. 374 s 3; 2005 SL No. 7 s 3
 sub 2008 Act No. 4 s 41
 amd 2011 SL No. 168 s 3; 2011 SL No. 222 s 3; 2013 SL No. 41 s 4(2)

SCHEDULE 2A—DANGEROUS DRUGS

ins 2000 Act No. 28 s 26 sch
 amd 2002 SL No. 255 s 7(1); 2002 SL No. 368 s 6
 om 2008 Act No. 4 s 42

SCHEDULE 3—SPECIFIED QUANTITIES FOR PARTICULAR DANGEROUS DRUGS

- sch hdg** ins 1997 SL No. 459 s 5(1)
amd 2013 SL No. 41 s 5(1)
- sch 3** (prev 1986 Act No. 36 sch 3)
amd 1987 Act No. 53 s 12; 1989 Act No. 34 s 23
sub 1990 Act No. 88 s 3 sch
amd 1996 Act No. 49 s 17
reloc 1996 Act No. 49 s 21
amd 1997 SL No. 303 s 4; 1997 SL No. 459 s 5(2)–(3); 1999 SL No. 41 s 4;
2001 SL No. 249 s 4; 2002 SL No. 255 s 7(1)–(2); 2002 SL No. 368 s 7;
2008 Act No. 4 s 43; 2009 SL No. 99 s 7; 2013 SL No. 41 s 5(2)

SCHEDULE 4—SPECIFIED QUANTITIES FOR PARTICULAR DANGEROUS DRUGS

- sch hdg** ins 1997 SL No. 459 s 6(1)
amd 2009 SL No. 99 s 8
- sch 4** (prev 1986 Act No. 36 sch 4)
amd 1996 Act No. 49 s 18
reloc 1996 Act No. 49 s 21
amd 1997 SL No. 459 s 6(2); 2001 SL No. 174 s 6; 2002 SL No. 255 s 7(1);
2008 Act No. 4 s 44; 2008 SL No. 144 s 4; 2013 SL No. 41 s 6

SCHEDULE 5—DANGEROUS DRUGS

- sch hdg** ins 1997 SL No. 459 s 7(1)
amd 2009 SL No. 99 s 8
- sch 5** (prev 1986 Act No. 36 sch 5)
amd 1987 Act No. 53 s 13; 1996 Act No. 49 s 19
reloc 1996 Act No. 49 s 21
amd 1997 SL No. 459 s 7(2); 2002 SL No. 255 s 7(1), (3)
sub 2008 Act No. 4 s 45

SCHEDULE 6—CONTROLLED SUBSTANCES

- sch hdg** amd 2009 SL No. 99 s 9
- sch 6** (prev 1986 Act No. 36 sch 6)
prev sch 6 om R1 (see RA s 40)
pres sch 6 ins 1995 Act No. 18 s 8
amd 1996 Act No. 49 s 20
reloc 1996 Act No. 49 s 21
amd 1997 SL No. 459 s 8; 2002 SL No. 255 s 7(1)
sub 2006 SL No. 71 s 5

SCHEDULE 7—CONDITIONS FOR PARTICULAR PERSONS AUTHORISED UNDER PART 4

- sch hdg** ins 1998 SL No. 348 s 5
- sch 7** sub 2002 SL No. 255 s 8

Denaturer

- s 1** ins 1998 SL No. 348 s 5
 sub 2002 SL No. 255 s 8
 amd 2009 SL No. 99 s 10

DPI researcher

- s 2** ins 1998 SL No. 348 s 5
 sub 2002 SL No. 255 s 8

Inspector

- s 3** ins 1998 SL No. 348 s 5
 sub 2002 SL No. 255 s 8

Seed supplier

- s 4** ins 1998 SL No. 348 s 5
 amd 1999 SL No. 235 s 3
 sub 2002 SL No. 255 s 8

Analyst

- s 5** ins 2002 SL No. 255 s 8

SCHEDULE 8—LICENCE CONDITIONS

- ins 1998 SL No. 348 s 5
 sub 1999 SL No. 235 s 4; 2000 SL No. 234 s 3; 2002 SL No. 255 s 8

SCHEDULE 8A—GROSS WEIGHT OF RELEVANT SUBSTANCES FOR SS 9A, 9B, 9C AND 9D OF ACT

- sch hdg** amd 2008 Act No. 4 s 46(1); 2013 Act No. 14 s 50
sch 8A ins 2006 SL No. 71 s 6
 amd 2008 Act No. 4 s 46(2)

SCHEDULE 8B—THINGS SPECIFIED FOR SS 9A, 9B, 9C AND 9D, AND PRESCRIBED FOR S 134, OF ACT

- sch hdg** amd 2008 Act No. 4 s 47(1); 2009 SL No. 99 s 11(1); 2013 Act No. 14 s 51
sch 8B ins 2006 SL No. 71 s 6
 amd 2008 Act No. 4 s 47(2); 2009 SL No. 99 s 11(2)

SCHEDULE 8C—PROHIBITED COMBINATIONS OF ITEMS

- ins 2006 SL No. 71 s 6

SCHEDULE 8D—RELEVANT DANGEROUS DRUGS

- ins 2006 SL No. 71 s 6

SCHEDULE 9—DICTIONARY

- ins 1998 SL No. 348 s 5
 sub 2002 SL No. 255 s 8
 def *condenser* ins 2006 SL No. 71 s 7
 def *distillation head* ins 2006 SL No. 71 s 7
 def *heating mantle* ins 2006 SL No. 71 s 7
 def *occupier's notice* reloc 1998 SL No. 348 s 3(1)
 om 2002 SL No. 255 s 8
 def *record of proceedings* reloc 1998 SL No. 348 s 3(1)
 om 2002 SL No. 255 s 8

Endnotes

def *search warrant* reloc 1998 SL No. 348 s 3(1)
om 2002 SL No. 255 s 8
def *splash head* ins 2006 SL No. 71 s 7

© State of Queensland 2013
Authorised by the Parliamentary Counsel